CarrollDNHudsonEB.Venous thromboembolism prophylaxis conversion in nonsurgical inpatients. Ann Pharmacother2003;37:1194–6. DOI 10.1345/aph.1C509.
2.
GeertsWHHeitJAClagettGPPineoGFColwellCWAndersonFAJrPrevention of venous thromboembolism. Chest2001;119(1 suppl):132S–75S.
3.
LechlerESchrammWFlosbachCW.The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis1996;26 (suppl 2):49–56.
4.
KleberFXWittCFlosbachCWKoppenhagenKVogelG.Study to compare the efficacy and safety of the LMWH enoxaparin and standard heparin in the prevention of thromboembolic events in medical patients with cardiopulmonary diseases (abstract). Ann Hematol1998;76(suppl 1):P261.
5.
MismettiPLaporte-SimitsidisSTardyBCucheratMBuchmullerAJuillard-DelsartDPrevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost2000;83: 14–9.
6.
SchachtnerJMGuharoyRMedicisJJNewmanNSpeizerR.Prevalence and cost savings of therapeutic interchange among US hospitals. Am J Health Syst Pharm2002;59:529–33.
7.
SchumockGTNutescuEAWaltonSMArondekarBVLewisRK.Survey of hospital policies regarding low-molecular-weight heparins. Am J Health Syst Pharm2002;59:534–8.
